A Phase 4, Interventional, Single-arm, Open-label Study Evaluating the Effect of Guselkumab on Cardiovascular Risk Surrogate Markers in Participants With Moderate to Severe Plaque Psoriasis
Latest Information Update: 12 Mar 2024
At a glance
- Drugs Guselkumab (Primary)
- Indications Plaque psoriasis; Psoriatic arthritis
- Focus Therapeutic Use
- Acronyms G-CARE
- Sponsors Janssen-Cilag
- 22 Aug 2023 Status changed from active, no longer recruiting to discontinued because a strategic decision was made not to further execute the study. This decision was not based on a safety concern.
- 19 Jul 2023 Status changed from recruiting to active, no longer recruiting.
- 19 Jul 2023 Planned End Date changed from 15 Oct 2024 to 4 Jul 2024.